BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36813626)

  • 21. [Molecular features of 109 patients with chronic myelomonocytic leukemia in a single center].
    Qu SQ; Pan LJ; Qin TJ; Xu ZF; Li B; Wang HJ; Sun Q; Jia YJ; Li CW; Cai WY; Gao QY; Jiao M; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):373-379. PubMed ID: 37550186
    [No Abstract]   [Full Text] [Related]  

  • 22. Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion.
    Castillo MI; Ribate VE; Muñoz CM; Santillana SG; Taboada SE; Casterá ME; Abinzano CMJ; Barranco IA; Nieto CR; Pampliega VM; Blanco ML; de Andrés ÁS; de Oteyza PJ; Del Castillo BT; Font GI; Cayuela JA; Díez-Campelo M; Sánchez AR; Vercet SC; Díaz TM;
    Cancer Med; 2023 Aug; 12(16):16788-16792. PubMed ID: 37403747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical features and biological implications of different U2AF1 mutation types in myelodysplastic syndromes.
    Li B; Liu J; Jia Y; Wang J; Xu Z; Qin T; Shi Z; Song Z; Peng S; Huang H; Fang L; Zhang H; Pan L; Hu N; Qu S; Zhang Y; Wu J; Liu N; Ru K; Huang G; Xiao Z
    Genes Chromosomes Cancer; 2018 Feb; 57(2):80-88. PubMed ID: 29057546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.
    Makishima H; Visconte V; Sakaguchi H; Jankowska AM; Abu Kar S; Jerez A; Przychodzen B; Bupathi M; Guinta K; Afable MG; Sekeres MA; Padgett RA; Tiu RV; Maciejewski JP
    Blood; 2012 Apr; 119(14):3203-10. PubMed ID: 22323480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The Correlation of Gene Mutation and Clinical Characteristics in Patients with Myelodysplastic Syndrome and Prognostic Analysis].
    Zhang WW; Zhang YL; Ren CC; Wu TK; Liu B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):176-183. PubMed ID: 38387918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive and prognostic value of gene mutations in myelodysplastic syndrome treated with hypomethylating agents: a meta-analysis.
    Hu C; Wang X
    Leuk Lymphoma; 2022 Oct; 63(10):2336-2351. PubMed ID: 35543621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.
    Jung SH; Kim YJ; Yim SH; Kim HJ; Kwon YR; Hur EH; Goo BK; Choi YS; Lee SH; Chung YJ; Lee JH
    Oncotarget; 2016 Aug; 7(34):55264-55275. PubMed ID: 27419369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact.
    Bacher U; Haferlach T; Schnittger S; Zenger M; Meggendorfer M; Jeromin S; Roller A; Grossmann V; Krauth MT; Alpermann T; Kern W; Haferlach C
    Br J Haematol; 2014 Mar; 164(6):822-33. PubMed ID: 24372512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The molecular pathogenesis of the myelodysplastic syndromes.
    Pellagatti A; Boultwood J
    Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors.
    Je EM; Yoo NJ; Kim YJ; Kim MS; Lee SH
    Int J Cancer; 2013 Jul; 133(1):260-5. PubMed ID: 23280334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations.
    Martín I; Villamón E; Abellán R; Calasanz MJ; Irigoyen A; Sanz G; Such E; Mora E; Gutiérrez M; Collado R; García-Serra R; Vara M; Blanco ML; Oiartzabal I; Álvarez S; Bernal T; Granada I; Xicoy B; Jerez A; Calabuig M; Diez R; Gil Á; Díez-Campelo M; Solano C; Tormo M;
    Br J Haematol; 2021 Aug; 194(4):708-717. PubMed ID: 34296432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2023 Jan; 87():100920. PubMed ID: 36216757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Genetics of Myelodysplastic Syndromes: Clinical Relevance.
    Chiereghin C; Travaglino E; Zampini M; Saba E; Saitta C; Riva E; Bersanelli M; Della Porta MG
    Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
    Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
    [No Abstract]   [Full Text] [Related]  

  • 36. Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes.
    Nagata Y; Makishima H; Kerr CM; Przychodzen BP; Aly M; Goyal A; Awada H; Asad MF; Kuzmanovic T; Suzuki H; Yoshizato T; Yoshida K; Chiba K; Tanaka H; Shiraishi Y; Miyano S; Mukherjee S; LaFramboise T; Nazha A; Sekeres MA; Radivoyevitch T; Haferlach T; Ogawa S; Maciejewski JP
    Nat Commun; 2019 Nov; 10(1):5386. PubMed ID: 31772163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes.
    Kanagal-Shamanna R; Montalban-Bravo G; Sasaki K; Darbaniyan F; Jabbour E; Bueso-Ramos C; Wei Y; Chien K; Kadia T; Ravandi F; Borthakur G; Soltysiak KA; Routbort M; Patel K; Pierce S; Medeiros LJ; Kantarjian HM; Garcia-Manero G
    Cancer; 2021 Oct; 127(19):3552-3565. PubMed ID: 34161603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators.
    Qiu J; Zhou B; Thol F; Zhou Y; Chen L; Shao C; DeBoever C; Hou J; Li H; Chaturvedi A; Ganser A; Bejar R; Zhang DE; Fu XD; Heuser M
    RNA; 2016 Oct; 22(10):1535-49. PubMed ID: 27492256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts.
    Chen Z; Wang SA; Goswami M; Tang G; Routbort MJ; Patel KP; Luthra R; Medeiros LJ; Ok CY
    Leuk Res; 2019 Nov; 86():106227. PubMed ID: 31557598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Somatic Gene Mutations with Risk of Transformation into Acute Myeloid Leukemia in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis.
    Sutandyo N; Mulyasari R; Kosasih A; Rinaldi I; Louisa M; Kevinsyah AP; Winston K
    Asian Pac J Cancer Prev; 2022 Apr; 23(4):1107-1116. PubMed ID: 35485665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.